No Shortage of Hepatitis C Treatments

In late 2013, the FDA approved Sovaldi as the first nucleotide analog polymerase inhibitor. This medication works by preventing the virus from copying genetic material to replicate, and is approved to treat four types of hepatitis C. Sovaldi is given with ribavirin or with pegylated interferon and ribavirin. The combination given depends on the type of hepatitis being treated. Sovaldi comes in tablet form and is taken once daily, either with or without food.